Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study
Steven Powell(Georgetown University), William C. Spanos(Sanford Health), John H. Lee(Sanford Health), Lora Black(Sanford Health), Christopher Sumey(Sanford Health), Juan Luis Callejas‐Valera(Sanford Health), M.J. Blanchard(Sanford Health), Julie Bykowski(University of California San Diego), Mark M. Gitau(Sanford Health), Kathryn A. Gold(University of California San Diego), Ryan K. Nowak(Sanford Health), Paul A. Thompson(Sanford Health), Steven McGraw(Montana Cancer Consortium), Michele Lohr(Sanford Health), Christie Ellison(Sanford Health), Christopher D. Fischer(Sanford Health), Ashley W. Jensen(Apple (Israel)), Ezra E.W. Cohen(University of California San Diego)
Cited by 119
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
|International Journal of Radiation Oncology*Biology*Physics|2009|984
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|652
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551